There are only two things the COVID-19 pandemic has offered. First, some people are going to die, and the second one some people are going to make a lot of cash, and if you’re in doubt just ask the Big pharma how many billions of dollars they earned from this pandemic.
One of the largest beneficiaries of Fauci’s own made virus in China is the US-based vaccine manufacturer Moderna Inc. After two years of the pandemic Moderna has made a huge turnaround from losing $747 million in 2020 to posting revenues of over $12,000,000,000 ($12B) in 2021.
And this revenue only came from Moderna’s only commercially available product it offers: the experimental mRNA Covid-19 vaccine. After hitting its $12B revenue last year, the company is now rewarding its top executive, CEO Stephanie Bancel, with a massive ‘change-in-control’ package that will pay him upwards of $900 million dollars if the company is sold or merged and he loses his job in the process.
Bancel who already owns a net worth of over 4.3 billion, a total of $926,000,000 will also be rewarded a ‘golden parachute’ was approved by the board of the Massachusetts-based vaccine manufacturer. The total new package will be almost 1,000% above (975%) his previously agreed upon severance agreement of $9.6 million.
According to the Daily Mail report, Bancel’s total payout is volatile because it will be paid out mostly in the form of stock options:
“Much of Bancel’s sky-high parachute is tied to Moderna’s stocks, but share prices have gone up and down during the pandemic, making it hard to determine how much they’ll be worth if and when Bancel cashes them out.
Moderna shares reached a record high of $497.49 each on August 10, 2021, before tumbling to $253.98 by December 31. On Thursday, one share was worth $139.52.”
According to the CNBC report, aside from the recent golden parachute that will be given to Bancel, he already received huge cash in 2021. He made over $18.2 million for his role as Moderna’s CEO after combining his $990,385 in salary, $15 million in stock, and a $1.5 million bonus.
Aside from him, Moderna’s top executives are also cashing out right alongside Bancel. A 165.9 million in stock option was also rewarded to President Stephen Hoge in 2021; this was added on top of his salary and bonuses, which totaled $7.8 million last year.
Moderna’s Chief Technical Officer, Juan Andres, is also raking in the dough, selling $194.3 million in stock and making $6.6 million from the company in 2021.
These three top executives capitalize on the crisis before it times out as they unloaded hundreds of millions in Moderna stock over the past year. The high stock price of $497.49 during the summer has cratered to where it currently sits at $139.52 per share, so time is of the essence with their firesale.
Sources: The Gateway Pundit, Daily Mail, CNBC